Tuddenham, John F. https://orcid.org/0000-0002-0186-2652
Taga, Mariko
Haage, Verena
Marshe, Victoria S.
Roostaei, Tina
White, Charles
Lee, Annie J.
Fujita, Masashi
Khairallah, Anthony https://orcid.org/0009-0001-7021-3058
Zhang, Ya
Green, Gilad
Hyman, Bradley https://orcid.org/0000-0002-7959-9401
Frosch, Matthew
Hopp, Sarah https://orcid.org/0000-0001-5228-0022
Beach, Thomas G.
Serrano, Geidy E.
Corboy, John
Habib, Naomi https://orcid.org/0000-0002-6049-2487
Klein, Hans-Ulrich https://orcid.org/0000-0002-6382-9428
Soni, Rajesh Kumar
Teich, Andrew F. https://orcid.org/0000-0002-1916-8490
Hickman, Richard A.
Alcalay, Roy N.
Shneider, Neil
Schneider, Julie https://orcid.org/0000-0002-9482-1752
Sims, Peter A. https://orcid.org/0000-0002-3921-4837
Bennett, David A.
Olah, Marta https://orcid.org/0000-0003-4945-855X
Menon, Vilas https://orcid.org/0000-0002-4096-8601
De Jager, Philip L. https://orcid.org/0000-0002-8057-2505
Article History
Received: 14 December 2023
Accepted: 13 August 2024
First Online: 15 October 2024
Competing interests
: R.N.A. is funded by the NIH, DoD, the Parkinson’s Foundation and the Michael. J. Fox Foundation. R.N.A. received consultation fees from Avrobio, Caraway, GSK, Merck, Ono Therapeutics and Genzyme/Sanofi. P.L.D. has served as a consultant for Biogen, Merck-Serono and PureTech. All other authors declare no competing interests.